• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin nanocapsules
Publication date: Available online 26 May 2018Source: Nanomedicine: Nanotechnology, Biology and MedicineAuthor(s): Tan Yang, Yuyuan Chen, Pengxuan Zhao, Huiying Xue, Jia You, Bin Li, Yong Liu, Chuanchuan He, Xiaojuan Zhang, Lingling Fan, Robert J. Lee, Lei Li, Xiang Ma, Chuanrui Xu, Guangya XiangResistance of hepatocellular carcinoma (HCC) to systemic chemotherapy is partially due to presence of drug-resistant cancer stem cells. Bmi1 protein is essential for survival and proliferation of HCC cancer stem cells (CSCs). Here, we report that Bmi1 siRNA (Bmi1siR) loaded in cationic nanocapsules of cisplatin (NPC) eliminated ste...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - July 10, 2018 Category: Nanotechnology Source Type: research

Enhancing the therapeutic effect via elimination of hepatocellular carcinoma stem cells using Bmi1 siRNA delivered by cationic cisplatin Nanocapsules
Publication date: Available online 26 May 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Tan Yang, Yuyuan Chen, Pengxuan Zhao, Huiying Xue, Jia You, Bin Li, Yong Liu, Chuanchuan He, Xiaojuan Zhang, Lingling Fan, Robert J. Lee, Lei Li, Xiang Ma, Chuanrui Xu, Guangya Xiang Resistance of hepatocellular carcinoma (HCC) to systemic chemotherapy is partially due to presence of drug-resistant cancer stem cells. Bmi1 protein is essential for survival and proliferation of HCC cancer stem cells (CSCs). Here, we report that Bmi1 siRNA (Bmi1siR) loaded in cationic nanocapsules of cisplatin (NPC) eliminated ...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - May 27, 2018 Category: Nanotechnology Source Type: research

Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer
Publication date: Available online 14 April 2018 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Sophia A. Shahin, Ruining Wang, Shirleen I. Simargi, Altagracia Contreras, Liliana Parra, Louise Qu, Wei Wen, Thanh Dellinger, Juli Unternaehrer, Fuyuhiko Tamanoi, Jeffrey I. Zink, Carlotta A. Glackin TWIST protein is critical to development and is activated in many cancers. TWIST regulates epithelial-mesenchymal transition, and is linked to angiogenesis, metastasis, cancer stem cell phenotype, and drug resistance. The majority of epithelial ovarian cancer (EOC) patients with metastatic disease respond wel...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - April 15, 2018 Category: Nanotechnology Source Type: research

Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment
Publication date: Available online 16 November 2017 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Narsireddy Amreddy, Anish Babu, Janani Panneerselvam, Akhil Srivastava, Ranganayaki Muralidharan, Allshine Chen, Yan D. Zhao, Anupama Munshi, Rajagopal Ramesh Co-administration of functionally distinct anti-cancer agents has emerged as an efficient strategy in lung cancer treatment. However, a specially designed drug delivery system is required to co-encapsulate functionally different agents, such as a combination of siRNA and chemotherapy, for targeted delivery. We developed a folic acid (FA) -conjugat...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 28, 2017 Category: Nanotechnology Source Type: research

A nano-enabled cancer-specific ITCH RNAi chemotherapy booster for pancreatic cancer
Publication date: Available online 6 October 2014 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Maria de la Fuente , Marie-Christine Jones , Manuel J. Santander-Ortega , Anja Mirenska , Preethi Marimuthu , Ijeoma Uchegbu , Andreas Schätzlein Gemcitabine is currently the standard therapy for pancreatic cancer. However, growing concerns over gemcitabine resistance mean that new combinatory therapies are required to prevent loss of efficacy with prolonged treatment. Here, we suggest that this could be achieved through co-administration of RNA interference agents targeting the ubiquitin ligase ITCH. S...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - November 4, 2014 Category: Nanotechnology Source Type: research